A Phase 3 interventional study of Adapalene and Benzoyl Peroxide Topical Gel and Epiduo Topical Product in Acne Vulgaris, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-11-08.
Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 19 open to participants now, 28 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 39th largest by enrollment of the 353 interventional ones that give a count, is one of 23 that started in 2017, is one of 76 in phase 3, and was the 241st registered.
792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →19 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 23 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 825 is above the median of 70 across 674 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Padagis LLC has 6 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test product
Drug: Adapalene and Benzoyl Peroxide Topical Gel
RLD product
Drug: Epiduo Topical Product
placebo product
Drug: Placebo
Test product
RLD product
Placebo gel
Mean Percent Change From Baseline in the Papules and Pustules Lesion Count
Time frame: Day 1 to week 12
Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count
Per protocol population
Time frame: Day 1 to week 12
| Milestone | Test Product | Reference Product | Placebo Product |
|---|---|---|---|
| Started | 329 | 331 | 165 |
| Completed | 261 | 256 | 140 |
| Not completed | 68 | 75 | 25 |
| percentage of lesion change | Perrigo Active | Reference Active | Perrigo Placebo |
|---|---|---|---|
| Mean Percent Change From Baseline in the Papules and Pustules Lesion Count | 68.18 ± 28.96 | 63.56 ± 31.57 | 50.72 ± 35.12 |
Per protocol population
| percentage of lesion change | Perrigo Active | Reference Active | Perrigo Placebo |
|---|---|---|---|
| Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count | 62.75 ± 28.09 | 60.78 ± 33.73 | 43.45 ± 36.30 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Perrigo Active | 0/329 (0%) | 0/329 (0%) | 0/329 (0%) |
| Reference Active | 0/331 (0%) | 0/331 (0%) | 0/331 (0%) |
| Perrigo Placebo | 0/165 (0%) | 2/165 (1.2%) | 0/165 (0%) |
| Event | Perrigo Active | Reference Active | Perrigo Placebo |
|---|---|---|---|
| Cervical RadiculopathyNervous system disorders | 0/329 | 0/331 | 1/165 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/329 | 0/331 | 1/165 |
| Age, Categorical(Participants) | Perrigo Active | Reference Active | Perrigo Placebo | Total |
|---|---|---|---|---|
| <=18 years | 160 | 161 | 76 | 397 |
| Between 18 and 65 years | 169 | 170 | 89 | 428 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Perrigo Active | Reference Active | Perrigo Placebo | Total |
|---|---|---|---|---|
| Female | 117 | 129 | 69 | 315 |
| Male | 212 | 202 | 96 | 510 |
| Ethnicity (NIH/OMB)(Participants) | Perrigo Active | Reference Active | Perrigo Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 126 | 120 | 53 | 299 |
| Not Hispanic or Latino | 203 | 211 | 112 | 526 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Perrigo Active | Reference Active | Perrigo Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 0 | 4 |
| Asian | 13 | 6 | 4 | 23 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 51 | 48 | 30 | 129 |
| White | 241 | 256 | 122 | 619 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 21 | 19 | 9 | 49 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Sep 2018, 9 months.
Results were first posted in Jan 2021, 2 years 3 months after primary completion. A results delay was requested in Oct 2019.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.